What happens when you combine a decade of science, a powerful entrepreneurial story, and two exponential waves—AI and digital biology?
You get Geneoscopy.
On the latest episode of The Scope Forward Show, I caught up with Dr. Erica Barnell—Co-founder and Chief Medical and Science Officer of Geneoscopy. If you don’t know Erica yet, you should. She and her team just raised $112 million in a tough VC environment. Their lead assay, ColoSense, is now the first FDA-approved, RNA-based, non-invasive diagnostic test for colorectal cancer and advanced adenomas.
But this conversation went far beyond funding and FDA milestones.
We talked about:
- What’s next in IBD precision diagnostics and biomarker innovation
- How AI has replaced costly bioinformatics layers and transformed their R&D
- Why AI is not “artificial” at all—and how to use it without fear
- How patients are being guided through diagnostics via smart automation (text, email, even Uber Health)
- Why GI, like OB/GYN, is primed for disruption
This wasn’t just a company update—it was a glimpse into the future of our entire field.
We’re in a convergence era. Biology is becoming programmable. Intelligence is being digitized. And GI—if we lean in—has a front-row seat to reinvent itself.